NASDAQ:ARCT - Get Free Report ) will be releasing its earnings data after the market closes on Wednesday, May 8th. Analysts expect Arcturus Therapeutics to post earnings of ($1.17) per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link .
Get Arcturus Therapeutics alerts:
Sign Up
Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report ) last released its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.69) by $1.37. The business had revenue of $33.99 million for the quarter, compared to the consensus estimate of $64.14 million. Arcturus Therapeutics had a negative net margin of 15.65% and a negative return on equity of 18.22%. On average, analysts expect Arcturus Therapeutics to post $-3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Arcturus Therapeutics Stock Performance Shares of Arcturus Therapeutics stock traded up $2.34 on Wednesday, reaching $27.91. The company had a trading volume of 939,753 shares, compared to its average volume of 458,263. The firm's 50 day moving average price is $33.16 and its two-hundred day moving average price is $29.90. The firm has a market cap of $751.34 million, a PE ratio of -26.84 and a beta of 2.60. Arcturus Therapeutics has a 52-week low of $17.52 and a 52-week high of $43.81.
Insider Buying and Selling at Arcturus Therapeutics In other Arcturus Therapeutics news, COO Pad Chivukula sold 8,565 shares of the stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $35.01, for a total value of $299,860.65. Following the sale, the chief operating officer now directly owns 490,883 shares of the company's stock, valued at approximately $17,185,813.83. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website . Insiders own 13.80% of the company's stock.
Analysts Set New Price Targets A number of equities research analysts have recently issued reports on the stock. HC Wainwright reissued a "buy" rating and issued a $60.00 price target on shares of Arcturus Therapeutics in a research note on Wednesday, March 20th. Citigroup boosted their price target on shares of Arcturus Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a research note on Thursday, February 8th. Finally, William Blair reissued an "outperform" rating on shares of Arcturus Therapeutics in a research note on Friday, March 8th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Arcturus Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $61.33.
View Our Latest Analysis on ARCT
Arcturus Therapeutics Company Profile (
Get Free Report )
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
Featured Articles
Before you consider Arcturus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcturus Therapeutics wasn't on the list.
While Arcturus Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
